Ian Mcbeath

Naegis Pharmaceuticals Inc. is a Canadian biopharmaceutical company developing novel, small molecules for the treatment of serious inflammatory diseases.Chronic inflammatory disease represents an enormous societal and economic burden, particularly in an aging population, impacting both quality and quantity of life. Naegis Pharmaceuticals Inc. isdriven to discover new therapies that target underlying chronic inflammatory processes in disease. The Naegis research team seeks to design new drugs that offer safer and more effective treatment options for patients, focusing first on serious eye conditions that result in damage to the back of the eye, with a program directed towards blocking the synthesis of pro-inflammatory mediators in disease.